The Federal Trade Commission announced Friday it has cleared the latest pharmaceutical merger proposal as a string of deals in the industry sweeps across the globe.
Forest Laborites has been cleared to acquire Furiex Pharmaceuticals, a deal made for $1.46 billion, according to reports. Forest first announced in late April that it plans to acquire the company for its gastrointestinal treatment portfolio.
The merger is one of many in the works for the pharmaceutical market, though not all are sure to consummate. Recently, Pfizer failed to acquire AstraZeneca despite several bids that ultimately reached a $119 billion offer. Additionally, Valeant is currently looking to acquire the maker of Botox, Allergan, and has also recently increased its offer.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI